Peel Therapeutics, a biotech company that translates nature's evolutionary outliers into new medicines, has closed a $20.0M Series A funding round. The firm focuses on developing treatments for patients with cancer and inflammatory diseases by redesigning what nature offers, using scientific and medical expertise to tackle solubility, scalability, and bioavailability. With a clinical-stage therapeutic pipeline, Peel aims to push the limits of biology to develop highly effective and safe medicines that transcend incremental improvements.















.png&w=3840&q=75)


.png&w=3840&q=75)